Thallium-201 Scintigraphy in Differentiated Thyroid Cancer: Comparison with Radioiodine Scintigraphy and Serum Thyroglobulin Determinations

Lalitha Ramanna, Alan Waxman, and Glenn Braunstein

Department of Nuclear Medicine and Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California

The role of thallium-201 (201TI) scintigraphy in the follow-up evaluation of differentiated thyroid carcinoma (DTC) is controversial. Desirable characteristics of 201TI scintigraphy including the potential for no thyroid hormone withdrawal, immediate imaging postinjection, and low radiation burden relative to iodine-131 (131I) suggests it is logistically superior to 131I scintigraphy. Fifty-two patients with DTC were evaluated with 201TI and 131I neck and chest images, and serum thyroglobulin measurements. In post-thyroidectomy and pre-131I ablation therapy patients, very little 201TI accumulation was noted within the thyroid bed, with discordantly increased 131I activity and normal serum thyroglobulin measurements. Twenty-nine percent of patients evaluated after 131I ablative therapy had elevated serum thyroglobulin levels and localized neck and chest abnormalities on 201TI scan that were not seen on 131I studies. Our data suggest that 201TI is more sensitive than 131I diagnostic (5 mCi) studies for detection of DTC, while 131I is more sensitive in detecting normal residual thyroid tissue postoperatively.


Despite some controversies, the treatment of differentiated thyroid cancer (DTC) includes removal of thyroid tissue by a combination of surgery and iodine-131 (131I) ablation therapy followed by replacement thyroid hormone. This approach is associated with decreased recurrence rate of carcinoma and probably increased survival (1-5).

Radioiodine scintigraphy is widely used and recommended for follow-up evaluation of DTC patients to detect residual, recurrent, or metastatic disease. Radioiodine scintigraphy has several disadvantages, including the need for thyroid hormone withdrawal which results in a finite period of hypothyroidism. In addition, 131I localization in the thyroid bed is not specific for tumor.

Following the development of radioimmunoassay techniques for serum thyroglobulin (Tg) determinations, there have been several reports regarding the role of serum Tg in the follow-up and management of patients with DTC (6-21). It is generally accepted that significant elevations in Tg usually reflect the presence of recurrent or metastatic thyroid carcinoma (6-21).

The use of thallium-201 (201TI) has been reported in the follow-up evaluation of DTC (22-24) with conflicting results. Thallium scintigraphy theoretically has several advantages over 131I. The examination does not require thyroid hormone withdrawal and can be performed immediately after injection requiring less than one hour of study time. Radiation exposure is acceptably small (25).

The purpose of the present study is to evaluate 201TI scintigraphy independently and in conjunction with serum Tg determinations and compare the results to 131I diagnostic studies in patients with DTC and to determine if 201TI scintigraphy has a role in the follow-up evaluation of thyroid carcinoma patients.

MATERIALS AND METHODS

Fifty-two patients with DTC had 72 sets of 131I studies, serum Tg determinations, and 201TI scans. The patient population consisted of 34 females and 18 males ranging in age from 16-76 yr. Histologically, 37 had predominant papillary carcinoma, 7 had predominant follicular elements, and the remaining 8 had a mixed pattern. In 21 patients, 131I and thallium scans were obtained prior to 131I ablation therapy 4-6 wk following a near total thyroidectomy. Thirty-one patients were studied with 131I and thallium 8-12 mo following 131I ablative therapy.

Surgical Considerations

All patients underwent a total thyroidectomy with lymph node sampling when possible. Surgical information was obtained from the surgeon directly regarding outcome of the procedure, including incomplete resection of tumor.

Radioiodine Scans

Scans were obtained 48 hr following oral administration of 5 mCi of 131I using a state-of-the-art Anger camera with a
high-energy collimator. Ten-minute spot images were obtained of the head, neck, chest, abdomen, and pelvis. All thyroid medications were discontinued 6 wk prior to the scan and replaced by triiodothyronine. Two weeks prior to the scan study, triiodothyronine was stopped. It has been previously demonstrated that this protocol results in near maximal endogenous TSH elevations (26-28). TSH measurements were done in all cases prior to therapy. patients were treated if TSH values were >35 uU/ml.

Thyroglobulin Measurements

Blood samples for serum Tg assays were drawn prior to any radiotracer administration while the patients were off their thyroid hormone therapy. The Tg levels were determined by a sensitive radioimmunoassay by Endocrine Sciences Laboratory (29). The sensitivity of the assay is 2 ng/ml with prior screening of serum for anti-thyroglobulin antibodies.

Thallium-201 Scans

Two minutes following an i.v. administration of 3 mCi 201TI, two 15-min anterior neck and chest images were obtained consecutively followed by a 10-min posterior image of the chest and a repeat 15-min anterior neck/chest image 60 min postinjection. An image with markers placed at the level of suprasternal notch and chin was also obtained for the purpose of defining the thyroid bed. A large field of view state-of-the-art Anger camera with a 3/8-in. sodium iodide crystal and a low-energy all purpose collimator was used.

In all patients, the thallium study was performed while the patient was still on full thyroid hormone replacement therapy. In the 31 postablative patients, 201TI scans were done 6 wk prior to the diagnostic 131I studies. In the 21 postsurgical, non-ablated patients, 201TI scans were done 1-4 days prior to the 131I study.

Interpretation of Results

Thallium-201 and 131I scans were visually read as positive when increased focal activity was present with respect to background activity. Serum Tg levels were considered abnormal in these thyroidectomized patients if the values were >10 ng/ml (21).

RESULTS

Serum Tg and scan results in 21 patients who had studies following thyroidectomy but prior to 131I ablative therapy are summarized in Table 1. Six of these patients had no detectable 201TI activity despite marked focal 131I accumulation within the thyroid bed. An example is shown in Figure 1. Tg evaluations in this group were less than 10 ng/ml. Seven patients in this group demonstrated mild diffuse thallium activity in the neck, which appeared markedly discordant from 131I studies where marked focal 131I accumulation within the thyroid bed was present. Two of these patients had Tg values >10 ng/ml. In eight patients, focal areas of 201TI accumulations were concordant with marked accumulation noted on 131I studies. Three of these patients had serum Tg values >10 ng/ml. Patients were known to have DTC residual following surgery. Figure 2 is an example of a patient with markedly elevated serum Tg. (Tg = 990 ng/ml).

In a separate sub-group of 31 patients who had prior total thyroidectomies followed by 131I ablative therapy at least 8-12 mo prior to the current studies, 51 follow-up examinations were performed. The results of 201TI, 131I, and serum Tg determinations are summarized in Table 2 and Figure 3. The striking finding in this group was the large number of discordant studies (19/51) in which 201TI examinations detected neck/chest accumulations that were not seen with 5-mCi 131I diagnostic scans. An example is shown in Figure 4. Three of these patients underwent biopsy and demonstrated DTC. The

<p>| Table 1 |
| Correlation of 201TI and 131I Diagnostic Scans and Serum Tg Values in DTC Patients Following Surgery but Prior to 131I Ablation Therapy |</p>
<table>
<thead>
<tr>
<th>No. of pts</th>
<th>201TI uptake</th>
<th>131I uptake</th>
<th>Serum Tg ng/ml (No. of pts)</th>
</tr>
</thead>
<tbody>
<tr>
<td>6</td>
<td>0</td>
<td>Focal</td>
<td>&lt;10 (6)</td>
</tr>
<tr>
<td>7</td>
<td>Mid diffuse</td>
<td>Focal</td>
<td>&gt;10 (2)</td>
</tr>
<tr>
<td>8</td>
<td>Focal</td>
<td>Focal</td>
<td>&gt;10 (3)</td>
</tr>
</tbody>
</table>

FIGURE 1
A 3-mCi 201TI study (A) and a 48-hr 5-mCi 131I study (B) in a patient 4 wk following "total" thyroidectomy for differentiated thyroid cancer. Note the lack of significant 201TI accumulation within the neck and the markedly increased 131I accumulation. This discordant pattern was present in 13 of 21 patients who had undergone "total" thyroidectomy and had not yet received ablative 131I therapy.

FIGURE 2
A 48-hr 5-mCi 131I scan (A) and a 201TI neck and chest study (B) in a patient 4 wk following total thyroidectomy demonstrates focal accumulations in the thyroid bed on both studies. The patient's serum Tg levels were markedly elevated (990 ng/ml). The patient had known residual thyroid cancer following surgery and the studies demonstrate a concordant pattern in which both thallium and thyroglobulin were positive. This pattern was noted in 8 of 21 patients. Three of the eight patients had either known residual thyroid cancer left in the neck or markedly elevated Tg levels.
serum Tg values in the 19 discordant patients ranged from 28-100 ng/ml (nl <10 mg/ml), suggesting a high likelihood for tumor.

Seven patients in the 19 patient discordant group underwent 100-150-mCi $^{131}$I therapy because of markedly elevated serum Tg levels (>500 ng/ml). Five of these patients demonstrated accumulation of $^{131}$I outside the thyroid bed (lung, mediastinal, and cervical lymph nodes) on the post-$^{131}$I therapy scans consistent with metastatic disease. An example is shown in Figure 4. There is also additional metastasis in the lungs not detected with $^{201}$Tt.

Fourteen patients who were $^{131}$I and $^{201}$Tt positive but Tg negative had activity confined to the area of the thyroid bed. An additional four patients demonstrated a positive $^{131}$I scan and no $^{201}$Tt uptake. All four had normal Tg levels and a low-level uptake of $^{131}$I limited to the thyroid bed, suggesting the presence of residual normal thyroid tissue.

**DISCUSSION**

Iodine-131 scintigraphy has played an integral role in the management of patients with DTC. The patients generally are treated with therapeutic doses of $^{131}$I until ablation of iodine-avid tissue is achieved using diagnostic $^{131}$I scans. The $^{131}$I studies are especially important in the early phases of patient management so that clinicians can determine the extent of disease, including distant metastasis as well as initial therapeutic response to large doses of $^{131}$I.

Many problems exist in performing the radioiodine studies. They are inconvenient to most patients in that a period of symptomatic hypothyroidism occurs. Thyroid hormonal withdrawal programs are generally required to raise the endogenous TSH levels in order to stimulate residual iodine-avid tissue, including metastasis, for optimal $^{131}$I uptake and detection. It has been suggested that elevated TSH levels may stimulate thyroid carcinoma (30). The test requires at least two patient visits to the examination facility and is accompanied by a modest radiation burden. Iodine-131 cannot differentiate between normal residual thyroid tissue within the neck and DTC. The scan results are also dependent on a number of factors including dose of $^{131}$I used, instrumentation, imaging time, biologic factors influencing the stimulation of residual tissue, and a number of other parameters which affect sensitivity of the scan results (31).

The possibility of utilizing other tests such as serum Tg and thallium have recently been studied with conflicting and, therefore, controversial results (22-24). Hoefnagel et al. states that thallium is a highly sensitive indicator of DTC, although not specific and, when employed in conjunction with serum thyroglobulin, the sensitivity for detection of DTC is better than that for $^{131}$I. Brendel et al. in a recent report stated that thallium imaging cannot be recommended as the only modality for the follow-up of patients with DTC since $^{131}$I scint...
tigraphy done with 100–150 mCi is far more sensitive (23).

In our series, there were two distinctly different pa-
tient populations. Those who had studies post-thyroid-
ectomy, but prior to high-dose 131I therapy, and those
who were studied post-thyroidectomy and returned for
follow-up studies 8–12 mo following at least one course
of ablative 131I therapy, (100–150 mCi). In the patient
group who underwent 201T1 scintigraphy post-thyroid-
ectomy, but prior to 131I therapy, a large percentage
(13/21 = 62%) demonstrated an unexpected discordant
imaging pattern with little or no 201T1 accumulation
seen in the thyroid bed, but marked focal accumulations
present on the 131I studies. This group was evaluated by
competent, experienced surgeons who felt that follow-
ing surgery there was no bulk tumor remaining. Tissue
that was left was considered to be residual normal
thyroid approximating 0.25–1.0 g in the thyroid bed.
Using 5 mCi of 131I, the normal residual thyroid tissue
was exceptionally well demonstrated with extremely
high target/non-target ratios and relatively high photon
yields for purposes of scanning. In contrast, the 201T1
studies in this group demonstrated minimal to no activ-
ity except in patients where there was a high suspicion
of significant residual tumor based upon incomplete
removal of the tumor surgically or high Tg levels. Since
the normal thyroid concentrates 2°IT1 less avidly than
131I, the discordance noted between the results with the
two agents may simply reflect differences in the quantity
of normal tissue remaining after surgery and marked
differences in tissue-to-background ratios.

In the post-thyroidectomy, post-131I ablation follow-
up group (31 patients), the assumption was that very
little if any normal residual thyroid tissue remained. In
this group, 16 of 51 studies demonstrated focal accumu-
lations of 201T1 along with elevated serum Tg values,
but normal findings on 5-mCi 131I scans. In 3 of the 16
patients, direct evidence for DTC was confirmed by
biopsy. An additional seven patients were given 100-
150 mCi of 131I and five demonstrated activity outside
the thyroid bed, where 201T1 was positive and 5-mCi 131I
was negative. These areas were considered as highly
probable to contain DTC, and in three patients CT
demonstrated abnormalities corresponding to the areas
of 201T1 increase. The remaining eight patients were not
evaluated further, but as discussed they had elevated Tg
values, raising the probability that DTC was responsible
for increased 201T1 activity.

These findings suggest that 201T1 studies are more
sensitive than 5-mCi 131I diagnostic studies in detecting
residual DTC in the post-ablative patient, but they are
not more sensitive when compared to therapeutic (100-
150 mCi) 131I scans, which confirms the findings of
Hoefnagel and Brendel (22–23). Increased sensitivity
of lesion detection with increasing 131I tracer doses has
been reported by several groups (26,31–33).

Fourteen patients in this series demonstrated positive
131I and thallium studies but had negative Tg determi-
nations. This group had scan activity limited to the
thyroid bed. It is most likely that the scan activity
represents normal residual thyroid tissue which was not
ablated with 131I. However, because patients in this
group were not biopsied, we are unable to rule out the
possibility of residual DTC being present in the thyroid
bed.

It has been demonstrated that thyroglobulin determi-
nations are most sensitive in detecting DTC when
the test is performed in patients who are highly TSH
stimulated (13,14). If we assume that the 14 patients
with iodine and thallium activity in the thyroid bed had
only residual normal thyroid with no DTC, our data
would suggest that Tg determinations are highly sensi-
tive in detecting residual or metastatic DTC. A true
sensitivity of Tg cannot be determined from this study,
as biopsies were not taken from the 14 patients with
only residual thyroid bed activity detected on thallium
and iodine.

To some degree, the interpretation of the data in this
study is speculative, since biopsies could not be ob-
tained in all patients and therapeutic dose 131I scans
were not performed in all patients. The study demon-
strates that 131I scintigraphy is a significantly more
sensitive test than 201T1 in detecting small amounts
of residual normal thyroid tissue. Conversely, 201T1
was more sensitive than 5 mCi of 131I in detecting residual
or recurrent DTC in 131I "ablated" patients who had
biopsy evidence of DTC or presumptive evidence on
the basis of elevated serum Tg or distant sites detected
with >100 mCi 131I.

The presence of pulmonary parenchymal metastasis
is probably better evaluated with 131I, since thallium is
normally taken up by the lungs initially and is slowly
cleared. Two patients imaged with thallium both early
and on delayed films (1 hr postinjection) failed to
conclusively demonstrate residual activity within the
pulmonary parenchyma, while the 131I was positive on
the posttherapeutic scan doses. Tg was also markedly
elevated in tissue cases.

We are currently attempting to define a strategy
which would minimize the necessity for diagnostic 131I
scans. This would prevent patients from unnecessarily
undergoing thyroid hormone withdrawal. Hoefnagel et
al. determined the sensitivity for 201T1 detection of
residual or recurrent DTC to be 94%. The same group
determined in their series that thyroglobulin had a
sensitivity of 74%. The combination of both 201T1 and
thyroglobulin had a sensitivity of 98% and a corre-
sponding specificity of 90%. The current study also
demonstrates a high sensitivity for tumor detection
using 201T1. The recurrence rate of DTC in patients
who have been ablated with 131I is relatively low (4,5). After
ablation has been established and with the low rate of
recurrence, either thallium or thyroglobulin may be sufficient to follow patients with DTC. If the 131I and 201Tl studies remain negative and no unusual physical findings are evident, then no additional 131I studies may be necessary.

It should be stressed that a highly reliable laboratory for Tg determinations be utilized and that thallium studies be performed using the new generation of high-resolution Anger camera equipment. In addition, a 10–15-min image of the neck and chest should be performed using at least 3 mCi of 201Tl. Focal abnormalities on thallium studies or changes in the patient’s clinical or laboratory status indicate the need to perform a diagnostic 131I scan with appropriate endogenous stimulation.

ACKNOWLEDGMENTS

This study was supported in part by E. I. du Pont de Nemours & Co. (Grant-CG-87010).

The authors thank Joyce Jenison for her invaluable secretarial help in the preparation of this manuscript.

REFERENCES


1977:419--431.

**SELF-STUDY TEST**

**Pulmonary Nuclear Medicine**

Questions are taken from the *Nuclear Medicine Self-Study Program I*, published by The Society of Nuclear Medicine

**DIRECTIONS**

The following items consist of a heading followed by lettered options related to that heading. Select the one lettered option that is best for each item. Answers may be found on page 474.

1. In which of the following clinical situations should the number of 99mTc-macroaggregated albumin particles administered for pulmonary perfusion imaging be reduced?
   A. A patient with documented pulmonary hypertension.
   B. A patient who has undergone pneumonectomy.
   C. An apprehensive patient who is moderately dyspneic and tachyplenic and has a mildly depressed arterial pO₂ on room air.
   D. A patient with chest pain and a known, long-standing ventricular septal defect.
   E. A patient in the respiratory intensive care unit who is intubated and gravely ill.

2. True statements concerning the sequence of ventilation and perfusion imaging include:
   A. Xenon-127 ventilation imaging can be performed after 99mTc perfusion imaging because the energy of the principal 133Xe photons is higher than that of the primary 99mTc photon.
   B. If 133Xe imaging is performed after a 99mTc study, simple computer processing readily permits subtraction of the 99mTc scatter contribution from the 133Xe image.
   C. An important advantage of performing a perfusion study before ventilation imaging is that the ventilation study can be avoided if the perfusion images are normal.
   D. If 133Xe imaging is performed after the 99mTc study, interference from the background technetium activity can be obviated by use of a 3-mCi dose of 99mTc and a 10-mCi dose of 133Xe.
   E. When 81Kr is employed, it is desirable to obtain alternating krypton and technetium image pairs in each of the standard projections.

3. Perfusion images show complete absence of perfusion to one lung with normal perfusion to the other lung. The clinical suspicion of pulmonary embolism is low. Which of the following possibilities are moderately or highly likely explanations for these findings?
   A. pneumonectomy
   B. complete collapse of one lung
   C. a hilar mass not evident on standard chest radiograph
   D. pulmonary embolism

4. True statements concerning the perfusion defect seen in the right lower lobe of the study shown in Figure 1 include:
   A. Acute pulmonary embolism is an unlikely cause.
   B. This appearance occasionally is seen with resolving pulmonary embolism.
   C. It is most likely due to centrally located emphysema.

**FIGURE 1**

(continued on p. 474)
Thallium-201 Scintigraphy in Differentiated Thyroid Cancer: Comparison with Radioiodine Scintigraphy and Serum Thyroglobulin Determinations

Lalitha Ramanna, Alan Waxman and Glenn Braunstein